American journal of perinatology
-
Randomized Controlled Trial Multicenter Study
A Double-Blind, Randomized, Placebo-Controlled Trial of 17 Alpha-hydroxyprogesterone Caproate in the Management of Preterm Premature Rupture of Membranes.
The objective of this study was to evaluate whether weekly administration of 17 α-hydroxyprogesterone caproate (17-OHPC) increases the number of women who achieve 34 weeks of gestation after preterm premature rupture of membranes (PPROM). ⋯ We did not identify any benefit from administration of 17-OHPC in pregnancies complicated by PPROM.